Cullinan Associates’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.29M | Sell |
46,101
-9,200
| -17% | -$245K | 0.1% | 111 |
|
|
2025
Q4 | $1.38M | Sell |
55,301
-32,700
| -37% | -$825K | 0.09% | 116 |
|
|
2025
Q3 | $2.24M | Buy |
88,001
+11,500
| +15% | +$284K | 0.15% | 100 |
|
|
2025
Q2 | $1.85M | Buy |
76,501
+11,847
| +18% | +$276K | 0.12% | 108 |
|
|
2025
Q1 | $1.64M | Buy |
64,654
+1,400
| +2% | +$36.6K | 0.12% | 110 |
|
|
2024
Q4 | $1.68M | Sell |
63,254
-1,650
| -3% | -$44.8K | 0.11% | 117 |
|
|
2024
Q3 | $1.88M | Sell |
64,904
-197,180
| -75% | -$5.75M | 0.11% | 117 |
|
|
2024
Q2 | $7.33M | Sell |
262,084
-16,118
| -6% | -$444K | 0.41% | 57 |
|
|
2024
Q1 | $7.72M | Buy |
278,202
+83,384
| +43% | +$2.31M | 0.43% | 58 |
|
|
2023
Q4 | $5.61M | Sell |
194,818
-91,992
| -32% | -$2.78M | 0.31% | 75 |
|
|
2023
Q3 | $9.51M | Sell |
286,810
-29,800
| -9% | -$1.05M | 0.55% | 46 |
|
|
2023
Q2 | $11.6M | Sell |
316,610
-9,014
| -3% | -$351K | 0.64% | 41 |
|
|
2023
Q1 | $13.3M | Buy |
325,624
+74,155
| +29% | +$3.2M | 0.78% | 36 |
|
|
2022
Q4 | $12.9M | Buy |
251,469
+76
| +0% | +$3.64K | 0.71% | 32 |
|
|
2022
Q3 | $11M | Buy |
251,393
+19,332
| +8% | +$939K | 0.69% | 41 |
|
|
2022
Q2 | $12.2M | Buy |
232,061
+46,392
| +25% | +$2.36M | 0.74% | 39 |
|
|
2022
Q1 | $9.61M | Buy |
185,669
+91,816
| +98% | +$4.76M | 0.5% | 55 |
|
|
2021
Q4 | $5.54M | Buy |
93,853
+11,983
| +15% | +$594K | 0.28% | 87 |
|
|
2021
Q3 | $3.52M | Sell |
81,870
-168,900
| -67% | -$7.48M | 0.19% | 99 |
|
|
2021
Q2 | $9.82M | Sell |
250,770
-28,177
| -10% | -$1.1M | 0.55% | 56 |
|
|
2021
Q1 | $10.1M | Sell |
278,947
-27
| -0% | -$959 | 0.58% | 49 |
|
|
2020
Q4 | $10.3M | Buy |
278,974
+3,879
| +1% | +$142K | 0.62% | 42 |
|
|
2020
Q3 | $9.58M | Buy |
275,095
+4,216
| +2% | +$148K | 0.62% | 38 |
|
|
2020
Q2 | $8.4M | Buy |
270,879
+1,893
| +0.7% | +$64.3K | 0.59% | 37 |
|
|
2020
Q1 | $8.33M | Buy |
268,986
+4,971
| +2% | +$169K | 0.68% | 34 |
|
|
2019
Q4 | $9.81M | Buy |
264,015
+3,042
| +1% | +$108K | 0.66% | 39 |
|
|
2019
Q3 | $8.9M | Sell |
260,973
-1,000
| -0.4% | -$36.4K | 0.63% | 45 |
|
|
2019
Q2 | $10.8M | Buy |
261,973
+7,721
| +3% | +$307K | 0.78% | 25 |
|
|
2019
Q1 | $10.2M | Sell |
254,252
-4,664
| -2% | -$187K | 0.77% | 28 |
|
|
2018
Q4 | $10.7M | Sell |
258,916
-5,903
| -2% | -$245K | 0.89% | 21 |
|
|
2018
Q3 | $11.1M | Sell |
264,819
-25,131
| -9% | -$967K | 0.8% | 25 |
|
|
2018
Q2 | $9.98M | Sell |
289,950
-19,183
| -6% | -$656K | 0.76% | 28 |
|
|
2018
Q1 | $10.4M | Sell |
309,133
-16,675
| -5% | -$573K | 0.79% | 27 |
|
|
2017
Q4 | $11.2M | Buy |
325,808
+1,686
| +0.5% | +$57.5K | 0.82% | 25 |
|
|
2017
Q3 | $11M | Sell |
324,122
-3,010
| -0.9% | -$96.7K | 0.85% | 26 |
|
|
2017
Q2 | $10.4M | Buy |
327,132
+23,114
| +8% | +$729K | 0.81% | 31 |
|
|
2017
Q1 | $9.87M | Sell |
304,018
-18,910
| -6% | -$596K | 0.8% | 30 |
|
|
2016
Q4 | $9.95M | Sell |
322,928
-23,367
| -7% | -$713K | 0.85% | 28 |
|
|
2016
Q3 | $11.1M | Sell |
346,295
-13,354
| -4% | -$447K | 0.95% | 20 |
|
|
2016
Q2 | $12M | Sell |
359,649
-738
| -0.2% | -$23.6K | 0.98% | 17 |
|
|
2016
Q1 | $10.1M | Buy |
360,387
+16,021
| +5% | +$458K | 0.87% | 22 |
|
|
2015
Q4 | $10.5M | Buy |
344,366
+329
| +0.1% | +$10.3K | 0.92% | 20 |
|
|
2015
Q3 | $10.3M | Buy |
344,037
+19,625
| +6% | +$629K | 0.94% | 20 |
|
|
2015
Q2 | $10.3M | Buy |
324,412
+4,405
| +1% | +$144K | 0.85% | 18 |
|
|
2015
Q1 | $10.6M | Sell |
320,007
-68,530
| -18% | -$2.18M | 0.82% | 17 |
|
|
2014
Q4 | $11.5M | Buy |
388,537
+445
| +0.1% | +$12.8K | 1.22% | 11 |
|
|
2014
Q3 | $10.9M | Buy |
388,092
+221,448
| +133% | +$6.22M | 1.24% | 11 |
|
|
2014
Q2 | $4.43M | Sell |
166,644
-147,288
| -47% | -$4.2M | 0.72% | 21 |
|
|
2014
Q1 | $9.57M | Buy |
313,932
+40,811
| +15% | +$1.22M | 1.09% | 15 |
|
|
2013
Q4 | $7.94M | Buy |
273,121
+64,265
| +31% | +$1.87M | 0.92% | 17 |
|
|
2013
Q3 | $5.69M | Buy |
208,856
+10,029
| +5% | +$273K | 0.76% | 25 |
|
|
2013
Q2 | $5.28M | Buy |
+198,827
| New | +$5.49M | 0.71% | 23 |
|
Other funds holding PFE
VCM
VPM
Cullinan Associates's PFE Position: Q1 2026 in Review
Cullinan Associates reduced its Pfizer (PFE) stake by 17% in Q1 2026, selling an estimated $245K and leaving 46,101 shares worth $1.29M. The position accounts for 0.1% of the portfolio, ranked #111.
Cullinan Associates first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.3M in Q1 2023. 2,935 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Cullinan Associates held 46,101 shares of Pfizer worth $1.29M as of Q1 2026.
- Cullinan Associates sold 9,200 Pfizer shares in Q1 2026, an estimated $245K.
- Pfizer made up 0.1% of Cullinan Associates's portfolio in Q1 2026, its #111 holding.
- Cullinan Associates first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Cullinan Associates's Pfizer position peaked at $13.3M in Q1 2023.
- 2,935 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Cullinan Associates's 13F filing for Q1 2026, filed 1 May 2026.